Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial LANCET Tcheng, J. E., O'Shea, J. C., Cohen, E. A., Pacchiana, C. M., Kitt, M. M., Lorenz, T. J., Greenberg, S., Strony, J., Califf, R. M., Buller, C., Cantor, W. J., Joseph, D. M., Kitt, M. M., Lincoff, A. M., Madan, M., Popma, J., Teirstein, P., Cohen, E., Balleza, L., Parsons, P., Lui, H., Young, J., Fox, R., Labinaz, M., Jelley, J., Williams, J., Cohen, D., Trovato, M., Smith, J., Henry, P., Chisholm, R., O'Donnell, D., Talley, J. D., Pacheco, R., Timmis, S., Muraka, A., Mann, T., Cubeddu, G., Tannenbaum, M., Greene, J., Santoian, E., Wash, M., Sheldon, S., Pronesti, L., Jain, A., Alonzo, M., Seidelin, P., Richards, J., Lopez, M., Dittenber, R., Johnson, K., Levine, G., Maresh, K., Ferrando, T., Sarembock, I., Snyder, L., Kieval, J., Herlan, L., Miller, M., Bembridge, D., Nair, R., Hickel, L., Kiernan, F., Murphy, D., Cloutier, J., Conn, E., Beardsley, J., Ritchie, M., Cragen, D., Jafar, M. Z., Counihan, P., Rosenfelder, D., Ducas, J., Montebruno, L., Carere, R., Radons, B., Williams, L., Owens, W., Dougal, R., Feldman, R., Audrain, D., Karamali, A., Smith, M., Blankenship, J., Demko, S. L., Thompson, M., Gacoich, G., Chiodo, V., Noll, P., Ledley, G., Miller, C., Felten, W., Garner, B., Chandler, A. B., Easler, P., Albin, G., Page, A., Maddox, W., Allen, S., Gilchrist, I., Moore, R., Zimmerman, H., Curtis, M., Hildebrand, K., Greene, R., Healy, E., Meengs, W., Carson, D., George, J., Roncevich, T., Aharonian, V., Browning, R., Kostuk, W., Carr, S., Feit, F., Gostomsky, B., BUTMAN, S., Hannah, E., Hassel, C. D., Hartley, D., Shook, T., Hiller-Mullin, S., Brill, D., Dillion, M., Armstrong, B., Kerns, D., Pichard, A., Okubagzi, P., Nasser, T., Driver, L., GARRETT, J., Boltey, L., Stouffer, G., Potter, M., Amidon, T., Eggert, S., Taussig, A., Potter, K., Natarajan, M., Tartaglia, C., WERNER, J., Dunlap, T., Harrold-Runge, P., Davidson, C., Goodreau, L., Herzog, W., Calamunci, N., Slater, A., Tormey, D., Phillips, W., White, D., Sridhar, K., WHITE, J., Goodman, D., Buchbinder, M., Nasser, V., Rapeport, K., Vorman, P., Weiner, B., Borbone, M., Shadoff, N., Paap, C., Rehman, A., Haag, E., Burchenal, J., Kioussopoulos, K., Senior, D., Senior, J., Piana, R., Kirshenbaum, J., Chan, S., Chowdry, A., Kraft, P., Clark, V., Fox, M., DEUTSCH, E., Shannon, T., Quesada, R., Brotherton, J., Murrin, C., Cinderella, J., Hearne, S., Seefried, V., Farah, T., Pakstis, D., Bartolet, B., Bond, C., Debarardinis, C., Montory, D., Smith, G., Gray, D., Phillips, P., Hathaway, S., Manoukian, S., Patrick, C., Yakubov, S., Brooks, J., Block, P., Block, B., Muhlestein, J. B., Kim, S., Shalev, Y., Schmidt, W., Resar, J., Citro, K., Stine, R., Zumbuhl, J., Moreyra, A., Kreiger, S., Berger, P., Cannon, C. P., Fisher, L., Hasselblad, V., Foster, A., Joseph, D., Madan, M., McLendon, C., Rund, M., Tillery, N., Wood, F., Mahaffey, K. W., Irwin, C., Kulick, D., Johnson, N., Chen, J., Greenberg, S., Hogeboom, C., Lorenz, T. J., Terifay, R., Strony, J., Veltri, E. 2000; 356 (9247): 2037-2044


The platelet glycoprotein IIb/IIIa inhibitors, although effective in reducing ischaemic complications of percutaneous coronary intervention, are used in few coronary stent implantation procedures. ESPRIT (Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy) is a randomised, placebo-controlled trial to assess whether a novel, double-bolus dose of eptifibatide could improve outcomes of patients undergoing coronary stenting.We recruited 2064 patients undergoing stent implantation in a native coronary artery. Immediately before percutaneous coronary intervention, patients were randomly allocated to receive eptifibatide, given as two 180 microg/kg boluses 10 min apart and a continuous infusion of 2.0 microg/kg/min for 18-24 h, or placebo, in addition to aspirin, heparin, and a thienopyridine. The primary endpoint was the composite of death, myocardial infarction, urgent target vessel revascularisation, and thrombotic bailout glycoprotein IIb/IIIa inhibitor therapy within 48 h after randomisation. The key secondary endpoint was the composite of death, myocardial infarction, or urgent target vessel revascularisation at 30 days.The trial was terminated early for efficacy. The primary endpoint was reduced from 10.5% (108 of 1024 patients on placebo [95% CI 8.7-12.4%]) to 6.6% (69 of 1040 [5.1-8.1%]) with treatment (p=0.0015). The key 30 day secondary endpoint was also reduced, from 10.5% (107 of 1024 patients on placebo [8.6-12.3%]) to 6.8% (71 of 1040 [5.3-8.4%]; p=0.0034). There was consistency in reduction of events across all components of the composite endpoint and among the major subgroups. Major bleeding was infrequent but arose more often with eptifibatide than placebo (1.3%, 13 of 1040 [0.7-2.1%]) vs 0.4%, 4 of 1024 [0.1-1.0%]; p=0.027).Routine glycoprotein IIb/IIIa inhibitor pretreatment with eptifibatide substantially reduces ischaemic complications in coronary stent intervention and is better than a strategy of reserving treatment to the bailout situation.

View details for Web of Science ID 000165994300009

View details for PubMedID 11145489